Bain Capital Life Sciences Investors, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001703031

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2024 · 25 positions · Total reported value $910.84M · Top-10 concentration 87.8% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 33.3% · 3 new · 3 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2024 13F filing, Bain Capital Life Sciences Investors, LLC disclosed 25 equity positions with a combined reported value of $910.84M. The filing implies a focused portfolio: its ten largest positions account for 87.8% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2024 were NUVL ($204.61M), NAMS ($201.20M), IRON ($80.93M). By sector, the heaviest allocations are Health Care 72.6%, Industrials 1.1%. Versus the prior quarter, allocation shifted toward Other (+4.6pp) and away from Health Care (-4.6pp).

Versus the prior quarter, Bain Capital Life Sciences Investors, LLC opened 3 new positions, trimmed 3 and fully exited 2, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 89% of names.

The largest new positions opened in Q2 2024 were IPSC ($13.80M).

Of the 2 positions fully exited versus the prior quarter, the largest were MDGL ($52.61M), NRIX ($16.65M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • IPSC CENTURY THERAPEUTICS INC · $13.80M

Fully Exited (vs previous quarter)

  • MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $52.61M
  • NRIX NURIX THERAPEUTICS INC · prev qtr: $16.65M

Insider Transactions (Form 4)

Latest Bain Capital Life Sciences Investors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-04-30 Sell Heartflow, Inc. 56,224 $30.05 SEC filing
2026-04-30 Sell Heartflow, Inc. 892,533 $29.18 SEC filing
2026-04-29 Sell Heartflow, Inc. 797,133 $29.37 SEC filing
2026-04-28 Sell Heartflow, Inc. 254,110 $30.51 SEC filing
2026-04-20 Buy Kailera Therapeutics, Inc. 1,562,500 $16.00 SEC filing
2026-04-20 Conversion Kailera Therapeutics, Inc. 4,145,768 — SEC filing
2026-04-20 Conversion Kailera Therapeutics, Inc. 16,875,000 — SEC filing

All insider transactions →

Fund Profile

Bain Capital Life Sciences Investors, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 21 positions worth $1.68B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 21 positions · $1.68B reported value (Q2 2026)
  • Top 10 holdings = 87.9% of reported value
  • Largest position: KLRA (KAILERA THERAPEUTICS INC) at 29.6%
  • Average position size: $80.10M

Sector Tilt

  • Health Care 99.0%
  • Industrials 0.9%
  • Materials 0.1%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 2 new, 2 added, 7 reduced, 1 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 72.6%
Materials 0.1%
Other 26.2%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.70M $204.61M 22.46%
22.46%
Hold
2 10.47M $201.20M 22.09%
22.09%
Hold
3 1.80M $80.93M 8.89%
8.89%
Add
4 3.01M $77.99M 8.56%
8.56%
Add
5 3.30M $62.10M 6.82%
6.82%
Hold
6 14.57M $58.70M 6.44%
6.44%
Hold
7 8.45M $41.40M 4.54%
4.54%
Reduce
8 3.37M $25.26M 2.77%
2.77%
Add
9 2.89M $24.82M 2.73%
2.73%
Hold
10 4.03M $22.88M 2.51%
2.51%
Hold
11 8.66M $17.41M 1.91%
1.91%
Hold
12 2.75M $14.19M 1.56%
1.56%
Hold
13 5.41M $13.80M 1.51%
1.51%
New
14 1.65M $12.34M 1.35%
1.35%
Add
15 16.92M $9.81M 1.08%
1.08%
Hold
16 1.03M $9.59M 1.05%
1.05%
Reduce
17 2.49M $8.23M 0.90%
0.90%
Hold
18 8.43M $5.57M 0.61%
0.61%
Hold
19 1.11M $5.14M 0.56%
0.56%
Reduce
20 2.00M $4.68M 0.51%
0.51%
Hold
21 3.79M $3.59M 0.39%
0.39%
Add
22 2.27M $2.65M 0.29%
0.29%
Add
23 1.80M $1.98M 0.22%
0.22%
Hold
24 1.00M $1.10M 0.12%
0.12%
Reduce
25 100.00K $872.00K 0.10%
0.10%
Hold

FAQ

What did Bain Capital Life Sciences Investors, LLC buy in 2024-Q2?

In its 2024-Q2 13F filing, Bain Capital Life Sciences Investors, LLC reported 25 equity positions worth $910.84M in aggregate; its largest disclosed positions were NUVL ($204.61M), NAMS ($201.20M), IRON ($80.93M).

How large is Bain Capital Life Sciences Investors, LLC's portfolio?

Bain Capital Life Sciences Investors, LLC reported $910.84M of long equity holdings across 25 positions as of 2024-Q2. Top-10 holdings account for 87.8% of reported value.

What is Bain Capital Life Sciences Investors, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/bain-capital-life-sciences-investors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →